BioSyent Inc. (RX) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and welcome to the BioSyent Inc. Q2 and first half 2026 results presentation. My name is René Goehrum, and I'm the president and CEO of the company. Before I dive into today's presentation, I just wanted to bring your attention to our forward-looking statements disclaimer. Undoubtedly, there will be some in this presentation. So if you're new to the BioSyent story, kind of checking in on us for the first time Just want to remind you that we are in the healthcare products business. We bring proven products to patients and their providers. Our areas of specialization are pharmaceuticals and oral health products, and we commercialize those products primarily in Canada. That's the largest revenue footprint that we have in the business. But on the pharmaceutical side, we have customers outside of Canada for certain of our brands that we own The IP or the brand itself. And we have every intention of expanding our oral health business to also generate sales outside of Canada. It's a quick look at our brand wall. So this is a mix of our oral health and pharmaceutical brands. Let me dive into the numbers for the second quarter and first half of the year. So on the left-hand side of your screen, you see a summarization of our reporting segments, the second quarter, generated just over $11.1 million of pharmaceutical revenue, which represented an increase of 14% to the year ago. I'm going to skip down. Our legacy business, insecticides, generated just over half a million dollars, a 32% increase to the year ago. And then our oral health business generated just over $8.2 million in the quarter. And there's no comparable for that. I will speak a little bit more about our oral health business Later on in the presentation, if you are an ongoing kind of follower of the BioSyen...